Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Anal Canal Carcinoma × Capecitabine × Clear all

Phase

Status

Unknown 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 59 Colorectal Neoplasms 51 Stomach Neoplasms 38 Rectal Neoplasms 36 Neoplasm Metastasis 15 Pancreatic Neoplasms 13 Triple Negative Breast Neoplasms 11 Neoplasms 11 Colonic Neoplasms 10 Nasopharyngeal Carcinoma 9 Esophageal Neoplasms 8 Locally Advanced Rectal Cancer 6 Cholangiocarcinoma 6 Biliary Tract Neoplasms 6 Esophageal Squamous Cell Carcinoma 5 Adenocarcinoma 5 Colorectal Cancer Metastatic 4 Carcinoma, Hepatocellular 4 Recurrence 3 HER2 Positive Metastatic Breast Cancer 3 Gallbladder Neoplasms 3 Anus Neoplasms 3 Advanced Breast Cancer 3 Squamous Cell Carcinoma of Head and Neck 2 Solid Tumors 2 Solid Tumor 2 Neuroendocrine Tumors 2 Head and Neck Neoplasms 2 Gastrointestinal Neoplasms 2 Digestive System Neoplasms 2

Interventions

dehydroftorafur 1 Taxes 1 Radiotherapy, Intensity-Modulated 1 Radiation 1 Platinum 1 Paclitaxel 1 Immune Checkpoint Inhibitors 1 Fluorouracil 1 Cisplatin 1 Chemoradiotherapy 1 Carboplatin 1 Capecitabine 1 1,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02560298 2023-06-22

InterAACT

Eastern Cooperative Oncology Group

Phase 2 Unknown

Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡